Dec 9, 2025 07:58AM UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results

Dec 8, 2025 08:01AM NeuroPace reports 77% seizure reduction in epilepsy trial at 18 months

Nov 24, 2025 08:00AM NeuroPace receives medicare reimbursement increases for RNS system procedures

Nov 10, 2025 09:21AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Nov 5, 2025 06:20AM NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners

Nov 5, 2025 06:04AM Cantor Fitzgerald Says NeuroPace Inc (NPCE) Remains a Top Pick

Nov 4, 2025 04:36PM NeuroPace (NPCE) Tops Q3 EPS by 9c

Sep 9, 2025 08:58AM 'NeuroPace Inc (NPCE) Remains Our Best Idea for 2025' — Cantor Fitzgerald

Aug 14, 2025 06:04AM NeuroPace Inc (NPCE) PT Lowered to $13 at Wolfe Research

Aug 13, 2025 05:22AM NeuroPace Inc (NPCE) PT Lowered to $15 at Wells Fargo

Aug 12, 2025 04:11PM NeuroPace (NPCE) Misses Q2 EPS by 4c ; Offers Guidance

Aug 1, 2025 07:30AM NeuroPace maintains Medicare reimbursement for epilepsy device

Jun 26, 2025 08:01AM Leerink Partners Reiterates Outperform Rating on NeuroPace Inc (NPCE)

Jun 25, 2025 07:06AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Jun 24, 2025 04:05PM NeuroPace (NPCE) Announces Strategic CFO Transition

Jun 16, 2025 07:00AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Jun 12, 2025 10:25AM UBS Reiterates Buy Rating on NeuroPace Inc (NPCE)

Jun 12, 2025 07:20AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Jun 4, 2025 04:10PM NeuroPace (NPCE) Secures Up to $75M in Debt Financing

Jun 2, 2025 06:53AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

May 28, 2025 06:45AM H.C. Wainwright Starts NeuroPace Inc (NPCE) at Buy

May 27, 2025 01:05PM Cantor Fitzgerald Pounding Table on NeuroPace Inc (NPCE): 'we would be buyers of NPCE on today's pullback'

May 27, 2025 11:26AM Leerink Partners Reiterates Outperform Rating on NeuroPace Inc (NPCE)

May 27, 2025 08:03AM NeuroPace (NPCE) Announces Preliminary Results from One-Year Data in NAUTILUS Study

May 19, 2025 06:46AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

May 13, 2025 04:13PM NeuroPace (NPCE) Tops Q1 EPS by 3c, provides guidance

Apr 14, 2025 04:07PM NeuroPace (NPCE) Provides Update on Tariff Status

Apr 14, 2025 07:03AM NeuroPace Inc (NPCE) PT Lowered to $17 at Cantor Fitzgerald

Apr 10, 2025 06:48AM NeuroPace Inc (NPCE) PT Lowered to $17 at Cantor Fitzgerald

Apr 8, 2025 08:02AM NeuroPace (NPCE) Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

Apr 2, 2025 04:07PM NeuroPace (NPCE) reports strategic refocusing of product portfolio

Mar 18, 2025 06:36AM Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Mar 17, 2025 07:38AM Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer

Mar 10, 2025 07:08AM NeuroPace Inc (NPCE) PT Maintained at $20 at Cantor Fitzgerald

Mar 5, 2025 07:07AM NeuroPace Inc (NPCE) PT Raised to $20 at Cantor Fitzgerald

Mar 4, 2025 04:09PM NeuroPace (NPCE) Tops Q4 EPS by 7c ; Offers Guidance

Feb 14, 2025 06:36AM NeuroPace (NPCE) Announces Pricing of Public Offering of $65M of Common Stock

Feb 13, 2025 04:34PM NeuroPace (NPCE) Announces $65M Proposed Share Offering

Jan 21, 2025 12:59AM UBS Starts NeuroPace Inc (NPCE) at Buy

Dec 17, 2024 05:35AM NeuroPace Inc (NPCE) PT Raised to $14 at JPMorgan

Nov 12, 2024 04:24PM NeuroPace (NPCE) Tops Q3 EPS by 8c, provides guidance

Nov 4, 2024 04:06PM NeuroPace (NPCE) Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

Oct 16, 2024 04:07PM NeuroPace (NPCE) Appoints Amy Treadwell as VP of HR

Sep 4, 2024 04:06PM NeuroPace (NPCE) Announces Two Management Appointments

Aug 14, 2024 05:28AM NeuroPace Inc (NPCE) PT Lowered to $14 at Wolfe Research

Aug 13, 2024 04:08PM NeuroPace (NPCE) Tops Q2 EPS by 4c, Beats on Revenue; Offers FY24 Revenue Guidance